local
DecisionDx®-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy
By By Castle Biosciences, Inc. at Denton Record-Chronicle
· June 25, 2026
· 1 min read
Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram
Why this matters in Denton News
For Denton residents diagnosed with melanoma, the latest study on DecisionDx-Melanoma's i31-SLNB test brings welcome news. By more accurately identifying patients at low and high risk of sentinel lymph node positivity, this test can help local doctors make more informed decisions about whether to proceed with sentinel lymph node biopsy. This is particularly relevant in a community like Denton, where access to specialized cancer care is a concern. With the i31-SLNB test outperforming the MIA nomogram, patients may be able to avoid unnecessary procedures, reducing the risk of complications and improving overall outcomes. As local healthcare providers consider adopting this new test, Denton patients can expect more personalized and effective care for this serious disease. The study's findings may also prompt local discussions about the role of innovative diagnostics in shaping cancer treatment protocols and improving patient outcomes in the Denton area.
About this story
Original reporting by Denton Record-Chronicle . Denton News surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit Denton Record-Chronicle . Have a tip or correction? Contact our newsroom .
Category: local ·
Published: June 25, 2026 ·
Source: Denton Record-Chronicle ·
Reading time: 1 min
Get more Denton News stories like this
Free weekly briefing covering local and other local news. Curated by our editorial team. No spam.
By subscribing you agree to our privacy policy . Unsubscribe anytime.
Frequently asked about this story
What is this story about? Newly published prospective study shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram
When was this published? This article was first published on June 25, 2026 by Denton Record-Chronicle and curated for Denton News readers.
Who reported this story? This story was reported by By Castle Biosciences, Inc. at Denton Record-Chronicle. To learn more about how Denton News selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more local coverage from Denton News, or browse our daily briefing and topic hubs .
← Back to all news
More local →
Today’s briefing
Subscribe to newsletter